Month: August 2025

Regency Centers Declares Quarterly Dividends

Written by Customer Service on August 6, 2025. Posted in Dividend Reports And Estimates.

JACKSONVILLE, Fla., Aug. 06, 2025 (GLOBE NEWSWIRE) — Regency Centers Corporation (“Regency Centers,” “Regency” or the “Company”) (NASDAQ: REG) announced today that the Company’s Board of Directors (the “Board”) declared quarterly cash dividends on Regency’s common stock, Series A preferred stock, and Series B preferred stock.On August 5, 2025, the Board declared a quarterly cash dividend on the Company’s common stock of $0.705 per share. The dividend is payable on October 2, 2025, to shareholders of record as of September 11, 2025. On August 5, 2025, the Board declared a quarterly cash dividend on the Company’s Series A preferred stock of $0.390625 per share. The dividend is payable on October 31, 2025, to shareholders of record as of October 16, 2025. On August 5, 2025, the Board declared a quarterly cash dividend on the Company’s...

United Maritime Reports Second Quarter and First Half Financial Results for the Periods Ended June 30, 2025

Written by Customer Service on August 6, 2025. Posted in Dividend Reports And Estimates.

Declares Quarterly Cash Dividend of $0.03 Per ShareHighlights (in million USD, except EPS & LPS) Q2 2025 Q2 2024 6M 2025 6M 2024Net Revenues $12.5 $12.4 $20.2 $23.0 Net income / (loss) $1.0 $0.7 ($3.5) ($0.7) Adjusted net income / (loss)1 $0.2 $0.9 ($4.2) ($0.2) EBITDA1 $5.9 $6.0 $6.6 $9.5 Adjusted EBITDA1 $5.1 $6.3 $6.0 $10.0 Earnings / (loss) per share Basic $0.11 $0.08 ($0.40) ($0.08) Earnings / (loss) per share Diluted $0.11 $0.07 ($0.40) ($0.08) Adjusted earnings / (loss) per share Basic1 $0.02 $0.10 ($0.48) ($0.02) Adjusted earnings / (loss) per share Diluted1 $0.02 $0.09 ($0.48) ($0.02) Other Highlights and Developments:Consistent Shareholder Returns: Declared a quarterly cash dividend of $0.03 per share...

FTAI Infrastructure Inc. Announces Agreement to Acquire the Wheeling & Lake Erie Railway Company

Written by Customer Service on August 6, 2025. Posted in Mergers And Acquisitions.

NEW YORK, Aug. 06, 2025 (GLOBE NEWSWIRE) — FTAI Infrastructure Inc. (NASDAQ:FIP) (the “Company” or “FIP”) announced today that it has agreed to purchase The Wheeling Corporation, owner of the Wheeling & Lake Erie Railway Company (the “W&LE”), for cash consideration of $1.05 billion from an entity controlled by Larry Parsons, the CEO of The Wheeling Corporation. The W&LE is a Class II regional freight railroad serving more than 250 customers along over 1,000 miles of track in the states of Ohio, Pennsylvania, West Virginia, and Maryland. The W&LE connects to Transtar’s Union Railroad Company, LLC outside of Pittsburgh, Pennsylvania. Simultaneously with the closing of the acquisition, FIP plans to refinance its existing10.50% senior notes and Series A preferred stock. The Company has received commitments for $2.25...

NKGen Biotech To Present on Allogeneic Enhanced NK Cells without Lymphodepletion in Solid Tumors at the 13th Annual Immuno-Oncology Summit

Written by Customer Service on August 6, 2025. Posted in Public Companies.

SANTA ANA, Calif., Aug. 06, 2025 (GLOBE NEWSWIRE) — NKGen Biotech, Inc. (OTC: NKGN) (“NKGen” or the “Company”), a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous and allogeneic natural killer (“NK”) cell therapeutics, today announced that Paul Y. Song, M.D., Chairman and Chief Executive Officer of NKGen, will present at the 13th Annual Immuno-Oncology Summit (the “Summit”) to be held in Philadelphia, PA, from August 11 – 13, 2025. The Summit is a leading global event in cancer immunotherapy. Organized by Cambridge Healthtech Institute, the summit brings together top experts from industry and academia to explore the latest advances in cell therapies, innate immunity, bispecifics, and translational strategies. With multiple scientific tracks, high-impact presentations,...

Merus to Present at the Canaccord Genuity 45th Annual Growth Conference

Written by Customer Service on August 6, 2025. Posted in Public Companies.

UTRECHT, The Netherlands and CAMBRIDGE, Mass., Aug. 06, 2025 (GLOBE NEWSWIRE) — Merus N.V. (Nasdaq: MRUS), an oncology company developing innovative, full-length multispecific antibodies and antibody drug conjugates (Biclonics®, Triclonics® and ADClonics®), today announced that Bill Lundberg, M.D., President, Chief Executive Officer of Merus, will participate in a fireside chat at the Canaccord Genuity 45th Annual Growth Conference on Wednesday, August 13, 2025 at 1:30 p.m. ET. The webcast of the presentation will be contemporaneously available on the Investors page of the Company’s website. The archived presentation will also be available there for a limited time after the event. About MerusMerus is an oncology company developing innovative full-length human bispecific and trispecific antibody therapeutics, referred to as Multiclonics®....

Pure Harvest Corporate Group Eliminates All Debt and Enters New Phase of Strategic Growth

Written by Customer Service on August 6, 2025. Posted in Public Companies.

GREENWOOD VILLAGE, Colo., Aug. 06, 2025 (GLOBE NEWSWIRE) — Pure Harvest Corporate Group, Inc. (OTC: PHCG), a diversified holding company focused on acquiring and revitalizing undervalued businesses, is pleased to announce that it has officially eliminated all remaining debt from its balance sheet, marking a major turning point in the Company’s transformation. Following a comprehensive effort to restructure liabilities and strengthen the Company’s financial foundation, Pure Harvest is now debt-free and positioned to accelerate its long-term vision with renewed focus and flexibility. This achievement clears the path for growth initiatives and strategic investments designed to drive lasting value for shareholders. “This is a pivotal moment for Pure Harvest,” said Richard Hawkins, Interim CEO and Chairman of the Company. “We’ve spent...

Holley Reports Second Quarter 2025 Results

Written by Customer Service on August 6, 2025. Posted in Earnings Releases And Operating Results.

SECOND CONSECUTIVE QUARTER OF CORE NET SALES GROWTHSUCCESSFUL TARIFF MITIGATION TO DATE THROUGH STRATEGIC SOURCING AND PRICING Strong first half results driven by continued execution of our 2025 strategic framework. Core business growth improved again in the second quarter. Focused execution on tariff mitigation brings greater guidance visibility. BOWLING GREEN, Ky., Aug. 06, 2025 (GLOBE NEWSWIRE) — Holley Performance Brands (NYSE: HLLY), a leader in automotive aftermarket performance solutions, today announced financial results for its second quarter ended June 29, 2025. Second Quarter Highlights vs. Prior Year PeriodNet Sales decreased (1.7)% to $166.7 million compared to $169.5 million last yearCore business net sales1 for the second quarter of 2025 grew by 3.9% compared to the second quarter of 2024 after excluding non-core...

Arbutus Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Written by Customer Service on August 6, 2025. Posted in Earnings Releases And Operating Results.

Q2 total revenue of $10.7M includes previously-deferred revenue following reacquisition of Greater China rights to imdusiran Dr. Roger Sawhney joins the Arbutus Board of Directors following resignation of Anuj Hasija Dr. Harry Janssen joins the Arbutus Scientific Advisory Board Strong financial position with cash, cash equivalents and marketable securities of $98.1M WARMINSTER, Pa., Aug. 06, 2025 (GLOBE NEWSWIRE) — Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus” or the “Company”), a clinical-stage biopharmaceutical company focused on infectious disease, today reported second quarter 2025 financial results and provided a corporate update. “We delivered a strong quarter, marked by positive quarterly earnings resulting from the conclusion of our Greater China partnership with Qilu,” said Lindsay Androski, President and CEO...

Lexicon Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Updates

Written by Customer Service on August 6, 2025. Posted in Earnings Releases And Operating Results.

Partnership discussions for pilavapadin remain underway following Phase 2b PROGRESS study results IND-enabling studies of LX9851 for obesity and related disorders on track for completion in 2025 with licensee Novo Nordisk expected to submit IND Enrollment completion for SONATA Phase 3 study in both obstructive and non-obstructive hypertrophic cardiomyopathy (HCM) on target for 2026 Conference call and webcast at 8:30 am ET THE WOODLANDS, Texas, Aug. 06, 2025 (GLOBE NEWSWIRE) — Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), today reported financial results for the three months ended June 30, 2025, and provided an update on key corporate milestones and accomplishments. “We continue to make great strides against the strategy we set forth as an R&D focused company,” said Mike Exton, Ph.D., Lexicon’s chief executive officer...

Inspired Reports Second Quarter 2025 Results

Written by Customer Service on August 6, 2025. Posted in Earnings Releases And Operating Results.

Revenue of $80.3 million, up 7% over prior year, driven primarily by record Interactive revenue, up 45% year-over-year Net Operating Income of $7.9 million, Net Loss of $7.8 million and Adjusted Net Loss of $5.6 million Adjusted EBITDA of $28.4 million, up 15% from last year driven by record Interactive Adjusted EBITDA, up 49% year-over-year Secured five-year partnership with Jenningsbet to supply approximately 570 Vantage terminals Successfully completed comprehensive debt refinancing, issuing £270 million senior secured notes and securing a new £17.8 million revolving credit facilityNEW YORK, Aug. 06, 2025 (GLOBE NEWSWIRE) — Inspired Entertainment, Inc. (“Inspired” or the “Company”) (NASDAQ: INSE), a leading B2B provider of gaming content, technology, hardware and services, today reported financial results for the three-month...

Month: August 2025

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals